← Search & browse all drugs
BLOOD AND BLOOD FORMING ORGANS › ANTITHROMBOTIC AGENTS › ANTITHROMBOTIC AGENTS › Platelet aggregation inhibitors excl. heparin
cilostazol
B01AC23
Forms & Strengths
- Tablets: 50mg, 100mg
- Extended-release tablets: 100mg, 200mg
Adult Dosing
- 100mg PO twice daily
- Maximum dose: 100mg PO twice daily
- Dose adjustment for renal impairment and elderly: 50mg PO twice daily
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
- Cilostazol is not recommended for use in pediatric patients
Indications
- Intermittent claudication
- Improvement of walking distance in patients with intermittent claudication
- Peripheral arterial disease (PAD)
Mechanism of Action
- Inhibits phosphodiesterase 3 (PDE3) enzyme
- Increases cAMP levels
- Vasodilatory effects on peripheral arteries
- Antiplatelet aggregation activity
Contraindications
- Heart failure of any severity
- Hypersensitivity to cilostazol or any component of the formulation
Adverse Reactions
- Headache
- Palpitations
- Abdominal pain
- Diarrhea
- Dizziness
- Hemorrhage
- Tachycardia
Drug Interactions
- Increased risk of bleeding with anticoagulants (e.g., warfarin, heparin)
- Increased risk of hypotension with nitrates
- CYP3A4 and CYP2C19 inhibitors (e.g., ketoconazole, itraconazole, erythromycin) increase cilostazol levels
- Aspirin may increase risk of bleeding when co-administered with cilostazol
Curated Content: Needs Vetting Before Put to Clinical Use